Sanofi's outlook excludes a return of generics to its cancer drug Eloxatin in the United States.
2
Sanofi said net sales of Eloxatin fell 2.9 percent and net sales of Ambien fell 64.6 percent in the fourth quarter.
3
Sanofi said that without the impact of copies of Ambien in the U.S. and Eloxatin in Europe, second-quarter sales would have been up 7.1 percent.
1
Furthermore, L-OHP and fluorouracil combination was shown to be synergistic both in experimental studies and in clinical trials.
2
Pre-clinical studies from human cell lines suggested that L-OHP was efficacious in treating advanced or recurrent colorectal cancer.
3
Thus, introduction of irinotecan and L-OHP into clinical use has been a major advances for patients with metastatic colorectal cancer.
4
Conclusion: Palliative second-line treatment according to the AIO regimen plus L-OHP is feasible in an outpatient setting and well tolerated by the patients.
Ús de oxaliplatin en anglès
1
Patients and methods: Forty-eight patients received the combination of raltitrexed plus oxaliplatin.
2
These data indicate that survivin may be a key target for oxaliplatin.
3
This study investigated the addition of oxaliplatin with and without preoperative radiotherapy.
4
The platinum-based chemotherapeutic agent oxaliplatin displays a wide range of antitumor activities.
5
Further investigations indicated that survivin promoter activity was also inhibited by oxaliplatin.
6
Progression-free survival is increased with the addition of oxaliplatin and fluorouracil chemotherapy.
7
Anti-IGF-IR MoAB plus oxaliplatin led to a significantly greater inhibition of tumor growth.
8
A stop and go oxaliplatin strategy has been recommended to reduce oxaliplatin-associated neuropathy.
9
Another promising agent is oxaliplatin, which showed activity as first-line and second-line treatment.
10
No response occurred when oxaliplatin was administered as a single agent.
11
Dose reductions of single-agent oxaliplatin are not indicated in patients with hepatic dysfunction.
12
However, the underlying molecular responses to oxaliplatin in esophageal cancer remain largely unknown.
13
But the resistance to fluorouracil and sensitivity to oxaliplatin vanished.
14
Celecoxib decreased cellular oxaliplatin accumulation and Pt-DNA adduction formation due to reduced drug influx.
15
The platinum derivative oxaliplatin is widely used in colorectal cancer.
16
In stage III colon cancer combination chemotherapy with oxaliplatin is the standard of care.